LSB YS Biopharma Return on Sales by Gross Profit

LSB (LakeShore Biopharma Co., Ltd.) - company brandmark

LakeShore Biopharma Co. (LSB) faces geopolitical pressure and regulatory risks in China during vaccine development. Absolute gross margins demonstrate the operational resilience of the business, where 0.00 is the current value of the metric. Financial stability relies on government procurement in China. Promotion and production efficiency are ensured through the engagement of external contract partners and logistics outsourcing.

LSB: LakeShore Biopharma Co. Gross Margin 05/29/2024 - 10/04/2025

Financial and market metric breakdowns for LakeShore Biopharma Co., Ltd. (LSB)

Basic company analysis:LSB - LakeShore Biopharma
Manufactured product of LakeShore Biopharma

LakeShore Biopharma Co. (LSB) revenues depend on the vaccine market share in China and the efficiency of cold chain logistics, which directly impacts the cost of goods sold. By analyzing the gross margin structure, an investor assesses the percentage of revenue minus direct production costs: an upward trend confirms R&D operational efficiency, while a decline signals a risk of falling profitability and a business revaluation.